| Bioactivity | Zanoterone is an orally active antagonist of the androgen receptor (AR) with a Ki of 2.2 μM. Zanoterone blocks the binding of androgens such as testosterone and dihydrotestosterone (DHT), inhibiting the androgen signaling pathway, thereby reducing androgen-dependent prostate hyperplasia and prostate cancer growth[1]. |
| CAS | 107000-34-0 |
| Formula | C23H32N2O3S |
| Molar Mass | 416.58 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Juniewicz PE, et al. Effect of combination treatment with zanoterone (WIN 49596), a steroidal androgen receptor antagonist, and finasteride (MK-906), a steroidal 5 alpha-reductase inhibitor, on the prostate and testes of beagle dogs. Endocrinology. 1993 Aug;133(2):904-13. |
Zanoterone
CAS: 107000-34-0 F: C23H32N2O3S W: 416.58
Zanoterone is an orally active antagonist of the androgen receptor (AR) with a Ki of 2.2 μM. Zanoterone blocks the bind
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.